Research Topics
| Deenan PillaySummaryAffiliation: University of Birmingham Country: UK Publications
| Collaborators
|
Detail Information
Publications
Emergence and control of resistance to antiviral drugs in resistance in herpes viruses, hepatitis B virus, and HIVD Pillay
Birmingham Public Health Laboratory, Birmingham Heartlands Hospital, Bordesley Green East
Commun Dis Public Health 1:5-13. 1998..At present, the clearest indication for such testing is in aciclovir-resistant herpes simplex infection. It is important that other resistance assays are subject to studies of clinical utility before their widespread use...- Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committeeD Pillay
Division of Immunity and Infection, University of Birmingham Medical School, Edgbaston, UK
AIDS 14:1111-6. 2000..A cohort of co-infected patients treated with lamivudine were studied in order to evaluate the differential effects of lamivudine on the two viral populations within the same individual after 44-52 weeks of therapy... - The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected populationD Pillay
PHLS Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham Medical School, Birmingham, UK
Antivir Ther 6:15-24. 2001.... - HIV viral load: the myth of the undetectable?Deenan Pillay
PHLS Antiviral Susceptibility Reference Unit, Public Health Laboratory, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK
Rev Med Virol 12:391-6. 2002..I also consider other possible uses of HIV-1 quantification in clinical practice, such as identifying the inherent potency of antiviral regimens... - Drug-resistant HIV-1 in the semen of men receiving antiretroviral therapy with acute sexually transmitted infectionsStephen Taylor
HPA Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham, UK
Antivir Ther 8:479-83. 2003..We conclude that in the presence of suboptimal ART, sexually transmitted infections may enhance the spread of drug-resistant HIV-1... - Identification of a transmission chain of HIV type 1 containing drug resistance-associated mutationsStephen Taylor
Public Health Laboratory Service Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham, Birmingham B9 5SS, UK
AIDS Res Hum Retroviruses 19:353-61. 2003..We provide "proof of principle" that such mutations can therefore become "fixed" within the circulating virus pool... - Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000Paul Scott
PHLS Antiviral Susceptibility Reference Unit, Birmingham, UK
J Antimicrob Chemother 53:469-73. 2004..Our findings are relevant to the increased transmission of HIV drug resistance observed over this period... - Analysis of HIV-1 variation in blood and semen during treatment and treatment interruptionBhudipa Choudhury
PHLS Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham Medical School, Birmingham, United Kingdom
J Med Virol 68:467-72. 2002..Once successful therapy had been recommenced, it was possible to distinguish distinct populations of virus in the two compartments. These data support the hypothesis that the male genital tract represents a distinct HIV-1 reservoir... - HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapyStephane Hue
Division of Immunity and Infection, University of Birmingham and Regional Health Protection Agency, Birmingham Heartlands Hospital, London, UK
AIDS 18:719-28. 2004..We wished to assess the potential of using HIV-1 pol gene for the identification of transmissions events by phylogenetic means in the era of antiretroviral drug selective pressure... - Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trialDeenan Pillay
Public Health Laboratory Service Antiviral Susceptibility Reference Unit, Birmingham Public Health Laboratory, Birmingham, United Kingdom
J Infect Dis 186:617-25. 2002..No differences were observed in the frequency of development of resistance mutations L90M (P=1.00) and D30N (P=.61) in B and non-B viruses. In conclusion, no evidence that subtype determined virologic response to therapy was found... - Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patientsLi Xu
PHLS Antiviral Susceptibility Unit, Division of Immunity and Infection, University of Birmingham Medical School, Birmingham, UK
AIDS 16:1684-6. 2002..Minimal variation in the HR-1 region of gp41 was observed, especially within the region responsible for T-20 resistance. Any subtype differences in T-20 susceptibility do not appear to be related to HR-1 genetic variation... - Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient manCalman MacLennan
MRC Centre for Immune Regulation, Division of Immunity and Infection, University of Birmingham, Birmingham, UK
Lancet 363:1509-13. 2004..Chronic infection with such polioviruses is a recognised complication of hypogammaglobulinaemia... - Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitorsDavid Dunn
MRC Clinical Trials Unit, London, UK
Antivir Ther 13:771-7. 2008..These changes might be expected to affect the prevalence and patterns of protease resistance in the population of patients who experience treatment failure... - Update of the drug resistance mutations in HIV-1: 2007Victoria A Johnson
Birmingham Veterans Affairs Medical Center and the University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
Top HIV Med 15:119-25. 2007 - HIV resistance and the developing worldRavindra Kumar Gupta
Department of Infectious Diseases, John Radcliffe Hospital, Oxford, UK
Int J Antimicrob Agents 29:510-7. 2007.... - The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapyDeenan Pillay
Centre for Virology, Division of Infection and Immunity, Royal Free and University College Medical School, Windeyer Institute, 46 Cleveland Street, London W1T 4JF, UK
AIDS 20:21-8. 2006..Transmission of drug-resistant HIV-1 is well recognized. However, the impact of such transmission on natural history of infection remains unknown... - A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trialHannah Green
MRC Clinical Trials Unit, London, UK
Antivir Ther 11:857-67. 2006..To evaluate the longer-term utility of genotypic resistance testing in HIV-1-infected children with virological failure... 
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillanceRobert W Shafer
Division of Infectious Diseases, Stanford University, Stanford, California, USA
AIDS 21:215-23. 2007..However, such programs will not produce comparable estimates unless a standardized list of drug-resistance mutations is used to define transmitted resistance...- Update of the drug resistance mutations in HIV-1: Fall 2005Victoria A Johnson
Veterans Affairs Medical Center, Birmingham, AL, USA
Top HIV Med 13:125-31. 2005..A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that in isolation may not reflect prior drug selective pressure or reduced drug susceptibility... - Update of the drug resistance mutations in HIV-1: Fall 2006Victoria A Johnson
Birmingham Veterans Affairs Medical Center and the University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
Top HIV Med 14:125-30. 2006..A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that in isolation may not reflect prior drug selective pressure or reduced drug susceptibility... - Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversityRobert Gifford
Department of Infection, University College London, UK
AIDS 20:1521-9. 2006..However, it is not clear how reliable standard genotyping of these sequences is for describing HIV-1 genetic variation and for detecting novel genetic variants and epidemiological trends... - Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA loadDaniela Bezemer
Municipal Health Service Amsterdam, The Netherlands
Antivir Ther 11:173-8. 2006..043). No difference in HIV-1 RNA load was observed. These results, together with the apparent pressure to mutate at the resistance-associated positions exemplify the decreased fitness of viruses carrying 21 5Y/F, 70R or 184V... - Transient viral load increases in HIV-infected children in the U.K. and Ireland: what do they mean?Katherine J Lee
MRC Clinical Trials Unit, London, UK
Antivir Ther 12:949-56. 2007..To investigate transient increases in viral load during sustained suppression in children in the UK and Ireland Collaborative HIV Paediatric Study (CHIPS)... - Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort studyAndrew N Phillips
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
Lancet 370:1923-8. 2007..We estimated the proportion of patients who had extensive triple-class failure during long-term follow-up and examined characteristics associated with an increased rate of failure... 
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?Loveleen K Bansi
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Hampstead Campus, Rowland Hill Street, London, NW3 2PF, UK
AIDS 22:349-56. 2008..We investigated whether previous treatment interruptions are associated with a raised risk of viral rebound in individuals who have attained virological suppression...- Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medicationWolfgang Stöhr
MRC Clinical Trials Unit, London, UK
Antivir Ther 13:675-85. 2008..The aim of this study was to examine factors influencing plasma concentration of efavirenz and nevirapine... - The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United KingdomHannah Green
HIV Group, Medical Research Council Clinical Trials Unit, 222 Euston Road, London, United Kingdom
J Acquir Immune Defic Syndr 49:196-204. 2008..The use of different lists of resistance mutations has resulted in estimates of transmitted HIV drug resistance (THDR) that are often not comparable... - Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integraseRichard E Myers
Virus Reference Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW95EQ, United Kingdom
J Virol 82:9228-35. 2008..The validation of covariation as a predictive tool will be dependent on monitoring the evolution of HIV-1 integrase under drug selection pressure... - UK HIV drug resistance database: background and recent outputsDavid Dunn
MRC Clinical Trials Unit, London, UK
J HIV Ther 12:97-8. 2007 - Antiretroviral resistance in the developing worldDeenan Pillay
Department of Virology, University College London, London, UK
J HIV Ther 12:95-6. 2007 - Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panelMartin S Hirsch
Harvard Medical School, Boston, Massachusetts, USA
Clin Infect Dis 47:266-85. 2008..As the roll out of antiretroviral therapy continues in developing countries, drug resistance monitoring for both subtype B and non-subtype B strains of HIV will become increasingly important... - Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation modelAndrew N Phillips
HIV Epidemiology and Biostatistics Group, Department of Primary Care and Population Sciences, and Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, University College London, London, UK
Lancet 371:1443-51. 2008..Our aim was to study the potential consequences of such monitoring strategies, especially in terms of survival and resistance development... - Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006Florence Damond
APHP, Hopital Bichat Claude Bernard, Laboratoire de Virologie, Paris, 75018 France
J Clin Microbiol 46:2088-91. 2008..Quantification varied between laboratories, and international standardization of quantification assays is strongly needed... - HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004Rana Chakraborty
Paediatric Infectious Diseases Unit, St George s Hospital, London
Pediatr Infect Dis J 27:457-9. 2008..Three-class resistance was noted in 42 samples (14.1%). Our study also highlighted underutilization of testing and the need for prompt genotyping after drug discontinuation which may have lead to an underestimation of HIV-1 resistance... - Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapyChristos Mihailidis
Chelsea and Westminster Hospital NHS Trust, London, UK
AIDS 22:427-30. 2008..Furthermore, the presence of V118I as the sole nucleoside reverse transcriptase inhibitor mutation should not be over-interpreted when deciding on therapeutic options... - Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational studyPatricia Cane
BMJ 331:1368. 2005..CONCLUSIONS: The United Kingdom has one of the highest reported rates of primary resistance to HIV drugs worldwide. Prevalence seems still to be increasing and is high in all demographic subgroups... - Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003Bernard Masquelier
Departement de Virologie et Immunologie biologique, CHU Bordeaux, France
J Acquir Immune Defic Syndr 40:505-11. 2005..To examine factors influencing the rate of transmitted drug resistance (TDR) among seroconverters, with particular emphasis on 3 widely used genotypic drug resistance algorithms... - Drug resistance mutations in HIV-1Victoria A Johnson
Veterans Affairs Medical Center, and University of Alabama School of Medicine, Birmingham, AL, USA
Top HIV Med 11:215-21. 2003..Drugs that have been approved by the US Food and Drug Administration (FDA) or available through expanded access protocols are included... - Transmission of HIV-1 drug resistanceJulian W Tang
Department of Virology, Windeyer Institute of Medical Sciences, Royal Free and University College Medical Schools, 46 Cleveland Street, London W1T 4JF, UK
J Clin Virol 30:1-10. 2004..As the use of HAART can only increase in the future, and compliance will always be a problem in such HAART-treated patients, baseline resistance testing should become a routine part of their management... - The effect of highly active antiretroviral therapy for HIV on the anti-HCV specific humoral immune responseEsteban Herrero-Martinez
Department of Virology, Royal Free and University College Medical School, London, United Kingdom
J Med Virol 72:187-93. 2004..The relationship disappeared or was obscured after therapy (R = 0.24, P = 0.30 and R = 0.16, P = 0.50, respectively). Thus, we show that HAART affects the HCV specific humoral immune responses without affecting the HCV RNA level... - Update of the drug resistance mutations in HIV-1: 2004Victoria A Johnson
Veterans Affairs Medical Center, Birmingham, AL, USA
Top HIV Med 12:119-24. 2004 - Current patterns in the epidemiology of primary HIV drug resistance in North America and EuropeDeenan Pillay
Department of Virology, Windeyer Institute, Royal Free and University College Medical School, University College London, London, UK
Antivir Ther 9:695-702. 2004.... - Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patientsCaroline A Sabin
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
Antivir Ther 8:301-8. 2003..New formulations of amprenavir, together with boosted regimens, may enhance the activity in the presence of protease inhibitor-resistant virus... - Long-term persistence of primary genotypic resistance after HIV-1 seroconversionDavid Pao
Royal Sussex County Hospital, Brighton, United Kingdom
J Acquir Immune Defic Syndr 37:1570-3. 2004.... - Resistance tests: what do clinical trials tell us?Nicola Price
J HIV Ther 7:80-6. 2002.... - Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infectionsDavid Pao
Department of GU Medicine, Brighton and Sussex University Hospitals, Brighton, UK
AIDS 19:85-90. 2005..More active identification of individuals during PHI, the management of STI and highly active antiretroviral therapy may all be useful methods to break transmission networks... - Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial)Diana M Gibb
Medical Research Council Clinical Trials Unit, London, UK
Antivir Ther 7:293-303. 2002.... - The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritisS Tariq Sadiq
Camden and Islington Community NHS Trust and Department of Sexually Transmitted Diseaeases and Virology, Royal Free and University College Medical School, University College, London, UK
AIDS 16:219-25. 2002..When BVL was poorly controlled by antiretroviral therapy, high SVL occurred during gonococcal urethritis, increasing the potential risk of transmitting both wild type and drug resistant strains of HIV-1... - Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United KingdomDeenan Pillay
Centre for Virology, Royal Free and University College Medical School, University College, London, United Kingdom
J Infect Dis 192:967-73. 2005..Method 2 also nearly doubles estimates of numbers of individuals infected with multiclass drug-resistant virus. Our results identify an urgent need for new drugs within existing classes and new classes of antiretroviral therapy... - The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patientsAlan Winston
Department of Genitourinary/HIV Medicine, Chelsea and Westminster Hospital, London, UK
AIDS 16:2087-9. 2002..Both genetic routes may compromise abacavir and tenofovir activity... - Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus Type 1 subtypes may influence mutational routes to drug resistanceAna T Dumans
Unidade de Genetica e Biologia Molecular, Universidade Federal do Estado do Rio de Janeiro (UNIRIO, Brazil
J Infect Dis 189:1232-8. 2004..CONCLUSIONS: The findings of the present study illustrate an important mechanism by which a subtype may determine genetic routes to resistance, with implications for treatment strategies for populations infected with HIV-1 subtype F... - Update of the Drug Resistance Mutations in HIV-1: 2005Victoria A Johnson
Veterans Affairs Medial Center, Birmingham, AL, USA
Top HIV Med 13:51-7. 2005..A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that, in isolation, may not reflect prior drug selective pressure or reduced drug susceptibility... - Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaborationRami Kantor
Division of Infectious Disease and Center for AIDS Research, Stanford University, Stanford, California, USA
PLoS Med 2:e112. 2005..The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate... - Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practiceAndrew N Phillips
AIDS 19:487-94. 2005..3195% CI 0.15-0.61; p = 0.0008). CONCLUSION: In routine practice, rates of viral load failure and of resistance detection in patients who started ART with three or four drugs are appreciable... - Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in womenInmaculada Jarrin
National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
Am J Epidemiol 168:532-40. 2008..74, 95% CI: 0.56, 0.98). Sex differences in HIV disease progression have become larger and statistically significant in the era of highly active antiretroviral therapy, supporting a stronger impact of health interventions among women... - World Health Organization/HIVResNet Drug Resistance Laboratory StrategySilvia Bertagnolio
World Health Organization, HIV Department, Geneva, Switzerland
Antivir Ther 13:49-57. 2008..As of August 2007, assessment for accreditation has been conducted in 30 laboratories, covering the WHO's African, South-East Asia, Western Pacific, and the Caribbean Regions... - Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptaseAlan Winston
Department of GU and HIV Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
AIDS 18:949-51. 2004 - Determinants of HIV drug resistance mutations in plasma virus after treatment interruptionDaniella Chilton
Mortimer Market Centre, Camden Primary Care Trust, London, UK
AIDS 19:2174-5. 2005..We conclude that resistance testing is of value up to 3 months after treatment interruption, and may convey some benefit up to 12 months... - Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependentJoke Snoeck
Rega Institute for Medical Research, Minderbroedersstraat 10, 3000 Leuven, Belgium
Antimicrob Agents Chemother 50:694-701. 2006..It is not yet known whether therapy response is subtype dependent, but the advice given to clinicians based on a genotypic interpretation algorithm differs according to the subtype... - Genetic analysis reveals the complex structure of HIV-1 transmission within defined risk groupsStephane Hue
Centre for Virology, Division of Infection and Immunity, University College London, 46 Cleveland Street, London W1T 4JF, UK
Proc Natl Acad Sci U S A 102:4425-9. 2005..Our results provide insights into the complexity of HIV-1 epidemics that must be considered when developing HIV monitoring and prevention initiatives... - Investigation of HIV-1 transmission events by phylogenetic methods: requirement for scientific rigourStephane Hue
AIDS 19:449-50. 2005 - Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell countAndrew N Phillips
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
AIDS 21:1717-21. 2007..To assess the absolute rate of AIDS and death in antiretroviral therapy (ART)-naive patients with a high CD4 cell count. Such information would be helpful in the design of a trial investigating early initiation of ART... - HIV phylogeneticsDeenan Pillay
BMJ 335:460-1. 2007 - Clinically validated genotype analysis: guiding principles and statistical concernsFrancoise Brun-Vezinet
Hospital Bichat Claude Bernard, Paris, France
Antivir Ther 9:465-78. 2004.... - Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV SeroconvertersKrishnan Bhaskaran
Medical Research Council Clinical Trials Unit, London, UK
AIDS 18:1471-3. 2004..The virological and host determinants of this possible phenomenon are worth further exploration... - Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1Robert J Gifford
Department of Infection, University College London, London, United Kingdom
J Virol 81:13050-6. 2007..The framework implemented here takes advantage of the vast amount of routinely generated HIV-1 sequence data and can provide epidemiological insights not readily obtainable through standard surveillance methods...